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Introduction {#sec1}
============

Microcephalic primordial dwarfism (MPD) is used to collectively describe a heterogeneous group of disorders characterized by significant in utero and postnatal growth retardation alongside marked microcephaly.[@bib1] Bloom syndrome (MIM: [210900](210900){#intref0010}) is also associated with prenatal growth restriction, short stature, and microcephaly. It is distinguished by an erythematous sun-sensitive facial rash that can become evident during childhood.[@bib2] A predisposition to the development of cancer in early adulthood is also seen, and both solid tumors and hematological malignancies are a major cause of early death.[@bib3] Additionally, a key cytogenetic feature of Bloom syndrome is an increased number of sister chromatid exchanges (SCEs).[@bib4] Notably, when molecular testing is inconclusive, a finding of elevated SCEs is currently utilized for diagnostic confirmation of Bloom syndrome (see GeneReviews in [Web Resources](#app3){ref-type="sec"}).

In 1995, Bloom syndrome was shown to be caused by mutations in *BLM* (MIM: [604610](604610){#intref0015}), which encodes a RecQ family DNA helicase.[@bib5] Mutations in *BLM* are typically biallelic loss-of-function mutations.[@bib6] BLM forms the BTRR complex with topoisomerase III alpha (TopIIIα) and RecQ-mediated genome instability proteins 1 and 2 (RMI1 and RMI2, respectively). Together, these proteins process double Holliday junctions (dHJs) that arise as a result of homologous-recombination-mediated repair of double-stranded DNA (dsDNA) breaks during DNA synthesis.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13] The process of dHJ dissolution requires two steps. First, the BTRR complex promotes the convergent branch migration of the dHJ to create a hemicatenane intermediate, and then this structure is decatenated by TopIIIα in concert with RMI1 and RMI2.[@bib14], [@bib15] Dissolution of a dHJ by this mechanism can be completed without any potentially detrimental exchanges between genetic markers flanking the original site of homologous recombination. The alternative processing of dHJs by Holliday junction resolvases (SLX-MUS81 and GEN1 nucleases) can yield crossover events, and increased usage of this pathway has been proposed to explain the increase in SCEs in BLM-deficient cells.[@bib16] Crossover events between homologous chromosomes can lead to loss of heterozygosity (LOH),[@bib17] which can be detrimental to cell survival and contribute to increased cancer predisposition.[@bib18] Additionally, unresolved recombination intermediates can persist into mitosis, leading to chromosome bridges, and act as a source of genome instability.[@bib19]

Here, we report the identification of pathogenic mutations in *TOP3A* (MIM: [601243](601243){#intref0020}) in ten individuals with Bloom syndrome-like phenotypic features and characterize the cellular consequences of these mutations.

Material and Methods {#sec2}
====================

Research Subjects {#sec2.1}
-----------------

Genomic DNA from the affected individuals and family members was extracted from peripheral blood by standard methods or obtained from saliva samples with Oragene collection kits according to the manufacturer's instructions. Informed consent was obtained from all participating families, and all procedures performed in studies involving human participants were in accordance with the Declaration of Helsinki. Research studies were approved by the Scottish Multicenter Research Ethics Committee (05/MRE00/74), the Hospital Universitario La Paz Ethical Committee (PI-2630), the Great Ormond Street Hospital Research Ethics Committee (09/H0706/66), the University Medical Center Göttingen Ethics Committee (vote ref. 3/2/1), and the Institute for Genomic Medicine at Columbia University (protocol AAAO8410).

Parents provided written consent for the publication of photographs of the affected individuals. For growth measurements, *Z* scores (standard deviations from population mean for age and sex) were calculated according to LMS (L, smooth curve; M, median; S, coefficient of variation) growth on the basis of British 1990 growth reference data.[@bib20] For calculation of *Z* scores for growth measurements published for Bloom syndrome,[@bib21] full-term gestation was assumed, and postnatal growth measurements were calculated from data provided for the 18- to 21-year age range.

Exome Sequencing and Sanger Sequencing {#sec2.2}
--------------------------------------

Exome sequencing and confirmatory capillary Sanger sequencing were performed according to standard methodologies as previously published.[@bib22], [@bib23] TOP3A and RMI1 variants were annotated with GenBank: [NM_004618.4](ncbi-n:NM_004618.4){#intref0025} and [NM_024945.2](ncbi-n:NM_024945.2){#intref0030} reference sequences, respectively.

Plasmid Construct and Protein Purification {#sec2.3}
------------------------------------------

### Cloning of the Mutant hTopIIIα Expression Vector {#sec2.3.1}

A plasmid encoding the wild-type (WT) *TOP3A* cDNA[@bib24] was modified by the Quickchange XL Site-Directed Mutagenesis Kit (Agilent technologies) with the following primers to recapitulate the deletion and frameshift present in subject P1: 5′-CCCTCCGTCACACGACTGTGCAGAAGGA-3′ (T3_FS_FW) and 5′-TCCTTCTGCACAGTCGTGTGACGGAGGG-3′ (T3_FS_RW).

### Expression and Purification of TRR {#sec2.3.2}

The previously described plasmids encoding RMI1 and RMI2[@bib13] and hTopoIIIα[@bib24] were co-transformed into *E. coli* Rosetta 2 cells, and the complex was expressed. The cells were disrupted in buffer A (50 mM Tris-HCl \[pH 7.5\], 0.5 M NaCl, 10% glycerol, 0.1% IGEPAL, 2 mM β-mercaptoethanol, 40 mM imidazole, 1 mM PMSF, and protease inhibitor tablet \[PI, EDTA-free, Roche\]) on ice before dounce homogenization and sonication. After the removal of cell debris by centrifugation, the lysate was affinity purified on a 5 mL HisTrap HP affinity column. The complex was further purified on a 5 mL HiTrap Heparin HP column in buffer B (50 mM Tris-HCl \[pH 7.5\], 10% glycerol, 0.1 mM EDTA, and 1 mM DTT) with a linear gradient of 200 mM to 1 M NaCl and then gel filtered on a 120 mL HiLoad 16/600 Superdex 200 column in buffer B containing 200 mM NaCl. Expression and purification of the mutant T^Thr812LeufsTer101^RR complex were performed in a similar manner. BLM was purified as described previously.[@bib25], [@bib26]

### dHJ Dissolution {#sec2.3.3}

The dHJ substrate construction and dissolution reactions were carried out as described previously.[@bib14]

Cell Culture {#sec2.4}
------------

Dermal fibroblasts were obtained by skin-punch biopsy and were maintained in amnioMAX C-100 complete medium (Life Technologies) in a 37°C incubator with 5% CO~2~ and 3% O~2~. siRNA oligonucleotides (siLUC: 5′-CUUACGCUGAGUACUUCGA-3′ \[siTopIIIα SMARTpool M-005279-01-0005, Dharmacon\]) were transfected into dermal fibroblasts with RNAiMAX (Life Technologies) according to the manufacturer's instructions.

Sister Chromatid Exchange Assay {#sec2.5}
-------------------------------

Dermal fibroblasts were treated with 10 μM BrdU for 48 hr followed by 0.5 μg/mL colcemid for 2 hr. Metaphases and nuclei were isolated in hypotonic buffer (0.25% KCl and 1% Na~3~C~6~H~5~O~7~), fixed with methanol and acetic acid (3:1 vol/vol), and dropped onto slides. Dried slides were rehydrated in PBS and then incubated with 2 μg/mL Hoescht 33342 stain in 2× saline sodium citrate (SSC) buffer (300 mM NaCl and 30 mM sodium citrate) for 15 min. Slides were then covered in 2× SSC buffer, irradiated in ultraviolet A at 5,400 J/m^2^, dehydrated in an ethanol series, and mounted in VECTASHIELD with DAPI.

### SCE Methodology for Analysis of P7 and P8 {#sec2.5.1}

Dermal fibroblasts were treated with 26.05 μM BrdU for 72 hr followed by 0.5 μg/mL colcemid for 5 hr and then harvested. Cells were resuspended in a pre-warmed hypotonic solution (0.051 M KCl) for 20 min at 37°C, fixed with methanol and acetic acid (3:1 vol/vol), and dropped onto slides. Samples were aged for at least 3 days and then stained with 1.56 μg/mL Hoechst 33258 (Sigma, B2883). Slides were irradiated in 2× SSC with ultraviolet C (356 nm) at 0.260 J/cm^2^, washed with 2× SSC, and stained with 10% Giemsa in phosphate buffer.

SCE analysis of peripheral-blood samples was performed according to standard methodology in a diagnostic lab setting.[@bib27]

Immunofluorescence and microscopy {#sec2.6}
---------------------------------

Mitotic abnormalities and G1-associated defects were analyzed as described previously.[@bib28], [@bib29] In brief, for mitotic analysis, cells were seeded onto 22 × 22 mm glass coverslips in 6-well plates. After 18 hr, cells were treated with 3.5 μM RO3306 for 6 hr for the induction of a late G2 arrest and were subsequently released into fresh media. After 45 min, cells were fixed with 4% paraformaldehyde containing 0.2% Triton X-100 in PBS for 20 min. For G1-associated defects, RO3306-treated cells were released into fresh media for 30 min. Prometaphase cells were shaken off and re-seeded onto glass slides coated with poly-[l]{.smallcaps}-lysine. After 4--6 hr, cells were fixed with 4% paraformaldehyde for 10 min and permeabilized with 0.5% Triton X-100 for 10 min. Fixed cells were incubated with antibodies specific to cyclin A (Santa Cruz Biotechnology, sc-596), 53BP1 (Santa Cruz Biotechnology, sc-515841), and PICH.[@bib30]

Immunoblotting {#sec2.7}
--------------

Cells were lysed in 50 mM Tris-HCl (pH 8), 280 mM NaCl, 0.5% NP40, 0.2 mM EDTA, 0.2 mM EGTA, and 10% glycerol supplemented with a protease inhibitor tablet (Roche Life Science). Protein samples were run on a 4%--12% NuPAGE Bis-Tris precast gel (Life Technologies) and then immunoblotted with anti-TopIIIα raised against amino acids 652--1,001 (Proteintech, 14525-1-AP) and actin (Sigma, A2066).

Results {#sec3}
=======

Identification of Mutations in *TOP3A* {#sec3.1}
--------------------------------------

In ongoing work to identify genes associated with microcephalic dwarfism, whole-exome sequencing (WES) was performed on subject P1, who had significant microcephaly and short stature (−5.7 and −4.4 standard deviations \[SD\], respectively). This identified the homozygous frameshift mutation c.2718del (p.Thr907LeufsTer101) (GenBank: [NM_004618.4](ncbi-n:NM_004618.4){#intref0035}) in *TOP3A* in chromosomal region 17p11.2. After interrogation of other cohorts and clinical contacts made through GeneMatcher,[@bib31] we subsequently ascertained a further nine individuals from seven families affected by biallelic deleterious *TOP3A* variants that had also been discovered by WES ([Table 1](#tbl1){ref-type="table"}). All variants identified were validated by Sanger capillary sequencing, and all parents were confirmed to be heterozygous carriers. Aside from the c.2718del variant (minor allele frequency = 0.00041%), none of the other variants were reported in GnomAD.[@bib33] Notably, four of the families from the United Arab Emirates, Syria, and Saudi Arabia (F2, F4, F6, and F7), were homozygous for the same variant.Table 1Identified *TOP3A* and *RMI1* Variants Associated with Microcephalic Dwarfism**FamilyIndividualGeneBiallelic Nucleotide MutationsPredicted Amino Acid Consequence(s)SexCountry of Origin**1P1*TOP3A*c.\[2718del\];\[2718del\]p.\[Thr907LeufsTer101\];\[Thr907LeufsTer101\]femaleUSA (Czech and Irish ancestry)2P2*TOP3A*c.\[2271dup\];\[2271dup\]p.\[Arg758GlnfsTer3\];\[Arg758GlnfsTer3\]femaleUnited Arab EmiratesP3*TOP3A*c.\[2271dup\];\[2271dup\]p.\[Arg758GlnfsTer3\];\[Arg758GlnfsTer3\]femaleUnited Arab EmiratesP4*TOP3A*c.\[2271dup\];\[2271dup\]p.\[Arg758GlnfsTer3\];\[Arg758GlnfsTer3\]maleUnited Arab Emirates3P5*TOP3A*c.\[527C\>T\];\[1072_1073dup\][a](#tblfn1){ref-type="table-fn"}p.\[Ala176Val\];\[Tyr359GlyfsTer17\]femaleJapan4P6*TOP3A*c.\[2271dup\];\[2271dup\]p.\[Arg758GlnfsTer3\];\[Arg758GlnfsTer3\]femaleSyria5P7*TOP3A*c.\[2428del\];\[2428del\]p.\[Ser810LeufsTer2\];\[Ser810LeufsTer2\]femaleSpainP8*TOP3A*c.\[2428del\];\[2428del\]p.\[Ser810LeufsTer2\];\[Ser810LeufsTer2\]maleSpain6P9*TOP3A*c.\[2771dup\];\[2771dup\]p.\[Arg758GlnfsTer3\];\[Arg758GlnfsTer3\]maleSyria7P10*TOP3A*c.\[2771dup\];\[2771dup\]p.\[Arg758GlnfsTer3\];\[Arg758GlnfsTer3\]femaleSaudi Arabia8P11*RMI1*c.\[1255_1259del\];\[1255_1259del\]p.\[Lys419LeufsTer5\]; \[Lys419LeufsTer5\]femaleTurkeyP12*RMI1*c.\[1255_1259del\];\[1255_1259del\]p.\[Lys419LeufsTer5\];\[Lys419LeufsTer5\]femaleTurkey--MC1[b](#tblfn2){ref-type="table-fn"}*TOP3A*c.\[298A\>G\];\[403C\>T\]p.\[Met100Val\];\[Arg135Ter\]femaleUK[^3][^4][^5]

Prenatal-Onset Growth Restriction and Microcephaly in Individuals with *TOP3A* Mutations {#sec3.2}
----------------------------------------------------------------------------------------

Prenatal growth restriction was evident from the substantially reduced birth weight in all individuals (mean weight −2.6 ± 0.9 SD; [Table 2](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}A). Postnatally, weight (mean −4.8 ± 1.8 SD), height (mean −3.9 ± 1.0 SD), and occipital-frontal circumference (mean −4.0 ± 1.2 SD) were significantly reduced. Growth parameters were similar to those previously reported for Bloom syndrome (mean birth weight −3.7 ± 1.2 SD, mean postnatal weight −3.8 ± 2.1 SD, and mean height −3.9 ± 1.1 SD).[@bib21] Although multiple café-au-lait patches were present in some individuals with *TOP3A* mutations, the classical erythematous malar facial rash was not apparent, and there were no reports of malignancies (although none had yet reached adulthood; [Table 3](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}B).Figure 1Variants in *TOP3A* Are Associated with Prenatal-Onset Growth Retardation and Microcephaly(A) Morphometric data for *TOP3A* individuals. A global reduction in growth is evident from before birth. *Z* scores (standard deviations from population mean for age and sex) for birth weight (Wgt), postnatal weight, height (Hgt), and occipital-frontal circumference (OFC). Dashed lines indicate the 95% confidence interval for the general population. Black circles indicate data points for individuals with *TOP3A* mutations. For comparison, gray bars indicate the mean value for cohorts of 89 (birth weight), 47 (current weight), and 52 (current height) subjects with Bloom syndrome.[@bib21](B) Photographs of facial features of individuals with *TOP3A* mutations.Table 2Growth Parameters of Individuals with *TOP3A* and *RMI1* Mutations**IndividualMutated GeneBirthPostnatalGestational Age (Weeks)WeightOFCLengthAge at ExamWeightOFCHeightkg*Z* Score (SD)**[a](#tblfn3){ref-type="table-fn"}**cm*Z* Score (SD)cm*Z* Score (SD)kg*Z* Score (SD)**[a](#tblfn3){ref-type="table-fn"}**cm*Z* Score (SD)cm*Z* Score (SD)**P1*TOP3A*371.35−3.927.5−4.238−5.45 months4.9−2.736−5.754.8−4.4P2*TOP3A*371.9−2.3NANANANA3 years9.5−3.747.5−2.384.5−2.8P3*TOP3A*372.2−1.6NANANANA8 years16.5−3.349.5−2.9112.5−2.7P4*TOP3A*402.2−2.9NANANANA10 years18.1−4.649.5−3.1113−4.1P5*TOP3A*351.91−1.331.8−0.243−1.815 years20−6.451−3.1138−3.7P6*TOP3A*NA2NANANANANA19 months5.17−7.544.3−3.064.3−5.8P7*TOP3A*381.90−2.830.0−2.741−4.13 years, 3 months7.21−7.044.2−5.378.7−4.7P8*TOP3A*341.41−2.528.5−2.242−2.17 years[b](#tblfn4){ref-type="table-fn"}10−2.945.8−5.098.1−4.5P9*TOP3A*402−3.4NANANANA11 years21.6−3.547.5−4.5125.6−2.7P10*TOP3A*361.6−2.7NANANANA4 years, 7 months9−6.145.5−5.091−3.3P11*RMI1*341.59−1.7NANANANA7 years14−3.846.5−5100−4P12*RMI1*381.80−3.1NANANANA13 years39−0.948−5135−2.9MC1[c](#tblfn5){ref-type="table-fn"}*TOP3A*NANANANANANANAadultNANANANA163NA[^6][^7][^8][^9]Table 3Clinical Phenotype of Individuals with *TOP3A* and *RMI1* Mutations***TOP3A**RMI1*P1P2P3P4P5P6P7P8P9P10MC1P11P12**Age5 months3 years8 years10 years15 years19 months3 years7 years11 years4 years, 7 monthsadult7 years13 yearsPrenatal-onset growth restrictionyesyesyesyesyesyesyesyesyesyesnoyesyesElevated sister chromatid exchangeyesyesyesNAyesNAyesyesyesNAnoNANACafé-au-lait maculesyesyesyesyesnoyesnoyesyesyesNAnonoDevelopmental delaymildnonononomild[a](#tblfn6){ref-type="table-fn"}nomildnomildNAmildnoCancer[b](#tblfn7){ref-type="table-fn"}nonononononononononoNAnonoDecreased subcutaneous fatnonononononoyesyesnoyesNAnonoGastroesophageal refluxyesNANANAnoyesnoNAnoNANAnonoDiabetes mellitusnonononononononononoNAnonoRecurrent infectionsyes[c](#tblfn8){ref-type="table-fn"}NANANAnononoNAyesyes[d](#tblfn9){ref-type="table-fn"}NAnonoMalar rashnonononononononononoNAnonoDilated cardiomyopathynonoyesyes (severe, deceased)yes (after heart transplant)normal echocardiogramNAyes[e](#tblfn10){ref-type="table-fn"} (asymptomatic)HCMnoNANANAMitochondrial DNA depletion in muscleNANANAN/Ayes (87%)NANANANANAyes (\>80%)NANAOtherCDH, gastrostomynoabnormal movements and ticsnohearing loss, CMAMMAnononomicrocytic anemia[f](#tblfn11){ref-type="table-fn"}noPEO, ataxianono[^10][^11][^12][^13][^14][^15][^16]

Cardiomyopathy Is Present in Some Individuals with *TOP3A* Mutations {#sec3.3}
--------------------------------------------------------------------

A single individual compound heterozygous for rare *TOP3A* variants has been reported recently with an adult-onset mitochondrial disorder (denoted as MC1 in [Table 1](#tbl1){ref-type="table"}).[@bib32] Whereas stature was normal (163 cm) in this adult female, several of the subjects reported here had clinical features that could also be attributable to mitochondrial dysfunction. P3 and P4 (family 2) had an additional diagnosis of dilated cardiomyopathy, which proved fatal in P4 at age 10 years. Another brother in this sibship died as a result of cardiomyopathy at the age of 13 years. Morphometric and other clinical information are not available for this individual. In P5 (family 3), a dilated cardiomyopathy was also reported, and skeletal muscle biopsy demonstrated 87% mitochondrial DNA depletion. P8 also had asymptomatic left ventricular dilatation noted on echocardiography, whereas P9 had hypertrophic cardiomyopathy.

Given the identification of multiple individuals with biallelic deleterious variants in *TOP3A*, alongside a consistent clinical phenotype across the cohort, we concluded that these mutations were likely to be pathogenic. We therefore pursued confirmatory functional studies by employing both biochemical and cell-biological approaches.

*TOP3A* Mutations Lead to Markedly Reduced Cellular Amounts of Enzyme TopIIIα {#sec3.4}
-----------------------------------------------------------------------------

Most of the identified *TOP3A* mutations are predicted to prematurely truncate the encoded protein ([Figure 2](#fig2){ref-type="fig"}A) and hence are likely to have significant effects on cellular protein amounts. We therefore assessed the amounts of TopIIIα in primary dermal fibroblast cell lines derived from P1, P7, and P8. Immunoblotting demonstrated that the amount of full-length TopIIIα was substantially lower in total cell lysates from all three individuals than in cell lines from unrelated control individuals and parents ([Figure 2](#fig2){ref-type="fig"}B).Figure 2Mutations in *TOP3A* Markedly Reduce Amounts of TopIIIα but Do Not Affect Its Intrinsic Decatenation Activity(A) Schematic of TopIIIα with locations of variants annotated. Colors are as follows: red, TOPRIM domain; purple, TOPA domain; and blue, GRF zinc-finger domain.(B) *TOP3A* mutations markedly reduce protein amounts. An immunoblot of a polyacrylamide gel is shown and was generated from total cell lysates from dermal fibroblast lines derived from affected individuals probed with an anti-TopIIIα antibody. siRNA depletion of TOP3A in a fibroblast line from control 2 was used to confirm the specificity of the antibody. C1 and C2 are unrelated control fibroblast lines. TopIIIα antibody was raised against amino acids 652--1,001.(C) Recombinant TopIIIα^Thr812LeufsTer101^ (denoted TopIIIα^P1^) is less stable than TopIIIα^WT^. An immunoblot of a polyacrylamide gel is shown and was generated from purified TopIIIα^WT^ and TopIIIα^P1^ proteins probed with an anti-TopIIIα antibody. Protein size markers are 250, 170, 140, 100, and 70 kDa.(D) Schematic depicting the BTRR complex and its role in dHJ dissolution. Homologous sister chromatids are shown in red and blue.(E and F) TopIIIα^P1^ is proficient for promoting dHJ dissolution with BLM in combination with RMI1 and RMI2. (E) Representative polyacrylamide gel demonstrating the enzyme-concentration dependence of the dHJ dissolution activity of TopIIIα^WT^ and mutant (TopIIIα^P1^) TRR complexes with 20 nM BLM at 37°C in 30 min. TRR was included in reactions at increasing concentrations ranging from 20 pM to 10 nM. A labeled circular oligonucleotide (lane 1) and dHJ (lane 2) were included as markers. (F) Quantification of the dHJ dissolution reaction shown in (E). The reaction was repeated twice more with very similar results.

In most subjects, the frameshift mutations would be expected to result in nonsense-mediated decay of *TOP3A* transcripts, explaining the consequent loss of TopIIIα. However, the homozygous frameshift mutation in P1 (c.2718del \[p.Thr907LeufsTer101\]) is at the 3′ end of the gene and is not predicted to result in NMD; instead, it would result in a protein with a length similar to that of the WT enzyme. The frameshift did, however, result in abolition of the C-terminal zinc-finger domain, whose precise cellular function remains to be defined. We therefore expressed recombinant TopIIIα^Thr907LeufsTer101^ in *E. coli* and purified it to homogeneity as a complex with the co-expressed RMI1 and RMI2 in order to characterize it further. Notably, in contrast to the TRR complex containing TopIIIα^WT^, the complex containing TopIIIα^Thr907LeufsTer101^ (hereafter referred to as TopIIIα^P1^) exhibited reduced stability during purification; lower yields and increased amounts of degraded products were evident on SDS-PAGE ([Figure 2](#fig2){ref-type="fig"}C). Nevertheless, when used in quantities equimolar to those of TopIIIα^WT^, TopIIIα^P1^ was proficient in a biochemical assay for dHJ dissolution when combined with other components of the BTRR complex. This indicates that this TopIIIα variant retains a near-normal level of single-stranded DNA (ssDNA) decatenation activity ([Figures 2](#fig2){ref-type="fig"}D--2F). Therefore, we concluded that the major consequence of the TopIIIα^P1^ variant, like the other truncating variants, is severe depletion of TopIIIα enzymatic activity in cells.

P5 was the only individual we identified to have an amino acid substitution, p.Ala176Val, that was present *in trans* with a frameshift mutation. This amino acid substitution is absent from GnomAD, and *in silico* analyses (MutationTaster, CADD, and SIFT) predict it to be deleterious. It is at a highly conserved residue ([Figure S1](#mmc1){ref-type="supplementary-material"}) within the TOPA domain ([Figure 2](#fig2){ref-type="fig"}A) and would therefore be expected to be highly deleterious to enzymatic function.

Given the above results and that *Top3a* is a developmentally essential gene in mice,[@bib34] we conclude that all of the identified mutations result in marked but most likely hypomorphic loss of function of TopIIIα as a result of a reduction in the cellular amount of the protein. Therefore, these mutations would be predicted to severely compromise the decatenation activity of the BTRR complex in dHJ dissolution *in vivo*. To assess this possibility, we next pursued cellular assays to assess SCE frequency.

SCEs Are Markedly Elevated in Individuals with *TOP3A* Mutations {#sec3.5}
----------------------------------------------------------------

dHJ can be processed by two pathways; first, dissolution by the BTRR complex yields non-crossover products only; second, resolution by endonucleases that cleave Holliday junctions generate both non-crossovers and crossover products that are visualized as SCEs ([Figure 3](#fig3){ref-type="fig"}A). To determine if dHJ dissolution is impaired in the cells of affected individuals, we assessed the frequency of SCEs. After BrdU incorporation, we performed differential sister chromatid staining on primary fibroblasts and PHA-stimulated peripheral blood leukocytes ([Figures 3](#fig3){ref-type="fig"}B and 3C). Cells from individuals with *TOP3A* mutations had substantially (3- to 6-fold) more SCEs, than cells from control individuals or heterozygous parents (p \< 0.0001 for all affected individual cell lines; [Figure 3](#fig3){ref-type="fig"}C). Therefore, excessive crossover recombination was evident in all tested individuals with *TOP3A* mutations, indicating that diagnostic cytogenetic assessment of SCE levels is predictive of *TOP3A* mutations as well as *BLM* mutations.Figure 3Individuals with *TOP3A* Mutations Have More SCEs, Reflecting Chromatid Hyper-recombination(A) Schematic of dHJ processing. dHJs are either dissolved by the BTRR complex or alternatively cleaved by structure-specific nucleases that lead to dHJ resolution.(B and C) BrdU strand-specific labeling of sister chromatids shows that TOP3A cells have more SCEs than control and parent cells. (B) Representative images of P1 and parent fibroblast cell lines. (C) Quantification of SCEs in fibroblast cell lines (P1, P5, P7, and P8) or PHA-stimulated lymphocytes derived from peripheral-blood samples (P2 and P3). The median value was plotted with more than ten metaphase spreads counted per subject. Pairwise non-parametric Mann Whitney tests were performed against parental control cells. F1, F2, and F5 SCEs were scored in independent laboratories.

Chromosome Segregation Defects and Genome Instability Occur in Cells with *TOP3A* Mutations {#sec3.6}
-------------------------------------------------------------------------------------------

Impaired dHJ decatenation can result in persistently entangled sister chromatids that impede chromosome segregation at mitosis.[@bib19] Therefore, we performed detailed characterization of the mitotic consequences of TopIIIα deficiency in primary fibroblasts from P1. DAPI staining demonstrated elevated amounts of chromatin bridges (control \[C\] = 0, parent = 0.3 ± 0.4, and P1 = 4 ± 0.6) and lagging chromatin and chromosomes (C = 0.9 ± 0.2, parent = 4 ± 0.7, and P1 = 9.2 ± 0.9) ([Figures 4](#fig4){ref-type="fig"}A and 4B), consistent with persisting chromosome entanglements. Additionally, increased numbers of ultrafine DNA bridges (UFBs) were revealed by immunostaining for PICH on DAPI-negative regions[@bib19] (C = 2.7 ± 0.3, parent = 13.1 ± 1.1, and P1 = 26.7 ± 3.8).Figure 4DNA Catenanes Persist into Mitosis in Cells with *TOP3A* Mutations, Leading to Chromosome Segregation Defects and Genome Instability(A and B) Chromosome segregation is impaired in *TOP3A*-deficient primary fibroblasts. (A) Representative images of chromatin bridges, lagging DNA (DAPI), and UFBs (detected by the presence of PICH and absence of DAPI stain). (B) Quantification of chromatin bridges, lagging DNA, and PICH-positive UFBs scored in control, parental, and P1 mitotic fibroblasts staged at anaphase B (experiments ≥ 3, n \> 50 cells, error bars = SEM). To enrich for mitotic cells, we treated fibroblasts with R03306 for 6 hr and released and fixed them after 45 min.(C) *TOP3A* P1 fibroblasts display significantly elevated amounts of micronuclei. Top: representative picture of control and P1 fibroblasts. Bottom: quantification of micronucleus containing interphase cells (experiments ≥ 3, n \> 500, error bars = SEM). To enrich for G1 cells, we released RO3306-treated cells into fresh media for 30 min and collected, re-seeded, and fixed prometaphase cells after 4--6 hr.(D) P1 fibroblasts with *TOP3A* mutations display significantly elevated numbers of 53BP1 bodies in G1 nuclei. Top: representative images of 53BP1 foci (red) and DNA (DAPI). Bottom: quantification of cells with at least four 53BP1 foci in G1 nuclei (negative for cyclin A) (experiments ≥ 3, n \> 500, error bars = SEM). Scale bar: 2 microns. Two-tailed t test was performed against parent cells.

We then examined the post-mitotic consequences of the observed chromosome segregation errors by enriching for G1 cells ([Figures 4](#fig4){ref-type="fig"}C and 4D). Micronuclei often arise from chromosome segregation errors,[@bib35] and analysis of DAPI-stained cells demonstrated substantially more micronucleated cells in the P1 fibroblast cell line than in control and parental cell lines (C = 0.4 ± 0.2, parent = 1.8 ± 0.5, and P1 = 7.5 ± 1.4). Elevated amounts of 53BP1 nuclear bodies were also seen in cyclin-A-negative (G1) cells, indicating the transmission of DNA damage from one cell cycle to the next[@bib36] (C = 0.8 ± 0.3, parent = 4.5 ± 0.5, and P1 = 11 ± 1.7). Altogether, we conclude that impaired dHJ decatenation in TopIIIα-deficient cells results in both abnormal recombination and mitotic errors that lead to accumulation of DNA damage. Because chromatin bridges and UFBs are also present in individuals affected by Bloom syndrome,[@bib19] these findings are concordant with a shared disease mechanism.

A Homozygous Truncating Variant in *RMI1* Is Associated with Microcephalic Dwarfism {#sec3.7}
-----------------------------------------------------------------------------------

Finally, through WES we also identified the homozygous truncating variant c.1255_1259del (p.Lys419Leufs^∗^5) in *RMI1* in two affected cousins (P11 and P12) from a consanguineous Turkish family (F8; [Table 1](#tbl1){ref-type="table"} and [Figure S3](#mmc1){ref-type="supplementary-material"}). Both individuals also had microcephalic dwarfism with a clinical phenotype and level of growth restriction similar to those of individuals with *TOP3A* mutations ([Figure 1](#fig1){ref-type="fig"}A and [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}).

Discussion {#sec4}
==========

Here, we report that biallelic mutations in *TOP3A* cause prenatal growth restriction, microcephaly, and short stature, a clinical phenotype overlapping that seen in Bloom syndrome. Furthermore, we have identified a rare *RMI1* truncating variant (allele frequency = 1.1 × 10^−5^) in two individuals. Given that no homozygous loss-of-function variants are reported in gnomAD, we expect this to be the cause of microcephalic dwarfism in individuals P11 and P12. However, it will be necessary to identify more individuals with other deleterious sequence variants to establish *RMI1* as a disease-related gene.

Notably, individuals with *TOP3A* mutations exhibit elevated amounts of SCEs on cytogenetic testing. Although cell lines were not available from P11 and P12, we also predict that increased SCEs will occur in cells with the homozygous RMI1 p.Lys419Leufs^∗^5 variant given the important role of this protein in the BTRR complex.[@bib9], [@bib10], [@bib37] For many years, the diagnosis of Bloom syndrome rested on a demonstration of elevated SCEs, and this has continued to be employed in cases where molecular testing is inconclusive (see GeneReviews in [Web Resources](#app3){ref-type="sec"}). Hence, analysis of other BTRR components is now warranted when elevated SCEs are detected. Indeed, given the clear phenotypic overlap between Bloom syndrome and individuals with *TOP3A* mutations, re-evaluation of individuals previously cytogenetically diagnosed with Bloom syndrome could be fruitful.

RMI2 is the fourth component of the BTRR complex. A single family in which two children were also found to have elevated SCEs was recently reported to have a homozygous deletion of *RMI2*; café-au lait macules were evident, but only one individual showed mild-growth impairment.[@bib38] Because RMI2 is not essential for BTR (BLM, TopIIIα, and RMI1) enzymatic function,[@bib12] a more subtle cellular and developmental phenotype might therefore result. It also remains possible that the BTR complex has functions independent of RMI2 given that BLM, TopIIIα, and RMI1 are conserved in all eukaryotes but RMI2 is absent in invertebrates and yeast.[@bib13]

Bloom syndrome is associated with a predisposition to both solid tumors and hematological malignancies.[@bib3] However, cancers have not been reported in our individuals with *TOP3A* mutations. Nevertheless, all are still children, and because malignancy in Bloom syndrome typically manifests in early adulthood, *TOP3A* mutations could also confer an increased risk of neoplasia.

Distinct from Bloom syndrome, some of our individuals with *TOP3A* mutations have clinical features consistent with mitochondrial dysfunction, and several exhibit a dilated cardiomyopathy. Notably, an individual with chronic progressive external ophthalmoplegia and cerebellar ataxia, along with a novel functional role for TopIIIα in the decatenation of mitochondrial DNA after its replication, has been recently reported[@bib32] (denoted as subject MC1). The compound-heterozygous mutations c.\[298A\>G\];\[403C\>T\], p.\[Met100Val\];\[Arg135^∗^\] could have milder consequences than those reported in our cohort, and consistent with this, we found that MC1 does not exhibit short stature ([Table 2](#tbl2){ref-type="table"}) or elevated numbers of SCEs in a primary fibroblast line derived from this individual ([Figure S2](#mmc1){ref-type="supplementary-material"}). Thus, it appears that the residual TopIIIα activity in MC1 is sufficient for the nuclear function of the BTRR complex in dHJ dissolution and for normal growth but could have become rate limiting for the role of TopIIIα in mitochondrial DNA replication.

Mechanistically, our cellular and biochemical studies suggest that the identified *TOP3A* mutations reported here are severe hypomorphs, consistent with the established essential cellular and developmental functions of TopIIIα.[@bib34] Given that marked growth restriction is common in individuals with *TOP3A* and *BLM* mutations, it seems likely that they have a shared pathogenic basis arising from reduced ssDNA decatenation activity of the BTRR complex. Persistence of unresolved hemicatenanes into mitosis leads to the formation of chromatin and ultrafine mitotic bridges that have previously been reported in Bloom syndrome[@bib19] and in individuals with microcephalic dwarfism and condensin mutations.[@bib39] The resulting genome instability arising from persistent chromatin bridges[@bib40], [@bib41] and micronuclei[@bib42] could therefore impair cell viability during development, causing microcephaly and global growth restriction. In summary, we demonstrate that mutations in *TOP3A* cause microcephalic dwarfism with increased SCE, implicating the BTRR complex as a cause of growth disorders.
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[^4]: Close to donor splice site of exon 10.
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[^6]: *Z* scores are the standard deviation from population mean for age and sex. The following abbreviation is used: NA, not available.

[^7]: Adjusted for gestation.
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